# Elisabeth Buchdunger

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/elisabeth-buchdunger/

## Facts

| Field | Value |
| --- | --- |
| Citations | 23,999 |
| Field | Chronic Myeloid Leukemia Treatments |
| h-index | 47 |
| i10-index | 63 |
| Last Known Institution | Novartis (Switzerland) |
| OpenAlex ID | https://openalex.org/A5083068452 |
| Works | 82 |

## Researcher papers

- [Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.](https://scholariq.org/papers/blockade-of-the-epidermal-growth-factor-receptor-signaling-by-a-novel-tyrosine/)
- [Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia](https://scholariq.org/papers/requirement-of-src-kinases-lyn-hck-and-fgr-for-bcr-abl1-induced-b-lymphoblastic/)

## Researcher topics

- [Chronic Myeloid Leukemia Treatments](https://scholariq.org/topics/chronic-myeloid-leukemia-treatments/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)
- [Eosinophilic Disorders and Syndromes](https://scholariq.org/topics/eosinophilic-disorders-and-syndromes/)

## Researcher university

- [Novartis (Switzerland)](https://scholariq.org/institutions/novartis-switzerland/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.